TRT(SH:600085) Bei Jing Shang Bao·2025-04-15 03:09Group 1 - The company achieved a revenue of 18.597 billion yuan in 2024, representing a year-on-year growth of 4.12% [1][2] - Net profit for the period was 1.526 billion yuan, with basic earnings per share at 1.11 yuan [2] - The total number of retail stores reached 1,251, with 250 new stores added in 2024 [2] Group 2 - The company’s major product strategy has led to significant revenue growth in key areas, with cardiovascular products generating 5.146 billion yuan (up 17.26%) and tonic products 2.127 billion yuan (up 22.98%) [3] - The company has established a comprehensive industry chain, including traditional Chinese medicine planting, processing, and retail, positioning itself well for future growth [6] Group 3 - The company is focusing on enhancing research and development, aiming to convert scientific achievements into marketable products, particularly in sleep-related and classic formulations [4] - Technological advancements are being integrated into production processes, with a digital production line completed to improve management efficiency [5] Group 4 - The company is expected to benefit from favorable market conditions and policy support, with the traditional Chinese medicine industry entering a phase of significant growth [6] - The company plans to accelerate the digital transformation of its production processes and optimize inventory and capacity management [5]